XASX
UWC
Market cap7mUSD
Jan 06, Last price
0.05AUD
Name
Hygrovest Ltd
Chart & performance
P/E
—
P/S
40.44
EPS
—
Div yield, %
—
Shrs. gr., 5y
-1.78%
Rev. gr., 5y
-62.09%
Revenues
260k
P
Net income
-131k
L-96.71%
CFO
-3m
L+128.34%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Hygrovest Limited operates as an investment specialist, primarily dedicated to cultivating capital growth for its shareholders. The company aims to deliver medium to long-term returns by strategically allocating capital across a diverse portfolio of publicly traded and private securities, along with other financial assets. It adopted its current name, Hygrovest Limited, in December 2021, having previously been known as MMJ Group Holdings Limited. The firm was established in 2014 and maintains its principal place of business in Sydney, Australia.
Related entities
Subsidiaries
PHYTOTECH MEDICAL (UK) PTY LTD
Key people
Non-Executive Chairman of the Board
Richard Jarvis
Chief Financial Officer · since 2016
Catherine Harvey
Chief Operating Officer · since 2016
Jim Hallam
Chief Financial Officer, Company Secretary · since 2018
Douglas James Halley
Director · since 2018
Michael Curtis
Non-Executive Director · since 2019
Non-Executive Director
Headquarters & legal address
'MLC CENTRE' SUITE 5706 LEVEL 57
19-29 MARTIN PLACE
SYDNEY, NSW 2000
AU
19-29 MARTIN PLACE
SYDNEY, NSW 2000
AU
Previous name
MMJ GROUP HOLDINGS LIMITED
Previous name
HYGROVEST LIMITED
Previous name
MMJ PHYTOTECH LIMITED
Previous name
PHYTOTECH MEDICAL LIMITED
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||